BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alabraba E, Joshi H, Bird N, Griffin R, Sturgess R, Stern N, Sieberhagen C, Cross T, Camenzuli A, Davis R, Evans J, O'grady E, Palmer D, Diaz-nieto R, Fenwick S, Poston G, Malik H. Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. European Journal of Surgical Oncology 2019;45:1660-7. [DOI: 10.1016/j.ejso.2019.04.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Mehmood A, Nawab S, Jin Y, Kaushik AC, Wei D. Mutational Impacts on the N and C Terminal Domains of the MUC5B Protein: A Transcriptomics and Structural Biology Study. ACS Omega 2023. [DOI: 10.1021/acsomega.2c04871] [Reference Citation Analysis]
2 Chmiel P, Gęca K, Rawicz-Pruszyński K, Polkowski WP, Skórzewska M. FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis? Cells 2022;11. [PMID: 36497187 DOI: 10.3390/cells11233929] [Reference Citation Analysis]
3 Wang G, Heij LR, Liu D, Dahl E, Lang SA, Ulmer TF, Luedde T, Neumann UP, Bednarsch J. The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review. Cancers (Basel) 2022;14. [PMID: 36497451 DOI: 10.3390/cancers14235969] [Reference Citation Analysis]
4 Hare AE, Makary MS. Locoregional Approaches in Cholangiocarcinoma Treatment. Cancers (Basel) 2022;14. [PMID: 36497334 DOI: 10.3390/cancers14235853] [Reference Citation Analysis]
5 Koshiol J, Yu B, Kabadi SM, Baria K, Shroff RT. Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015. BMC Cancer 2022;22:1178. [DOI: 10.1186/s12885-022-10286-z] [Reference Citation Analysis]
6 Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, Soong J, McCormick D, Tse E, O'Brien D, Bayat A, Ahn D, Davis SL, Park JO, Oh DY. Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology 2022. [PMID: 36152015 DOI: 10.1002/hep.32804] [Reference Citation Analysis]
7 Brown ZJ, Patwardhan S, Bean J, Pawlik TM. Molecular diagnostics and biomarkers in cholangiocarcinoma. Surg Oncol 2022;44:101851. [PMID: 36126350 DOI: 10.1016/j.suronc.2022.101851] [Reference Citation Analysis]
8 Islam MA, Barshetty MM, Srinivasan S, Dudekula DB, Rallabandi VPS, Mohammed S, Natarajan S, Park J. Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study. Biomolecules 2022;12:1279. [PMID: 36139117 DOI: 10.3390/biom12091279] [Reference Citation Analysis]
9 Leem G, Jang S, Cho J, Jo JH, Lee HS, Chung MJ, Park JY, Bang S, Yoo D, Cheon H, Kim J, Lim K, Jung I, Im J, Chung Y, Park SW. Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. Cancers 2022;14:4229. [DOI: 10.3390/cancers14174229] [Reference Citation Analysis]
10 Guo H, Qian Y, Yu Y, Bi Y, Jiao J, Jiang H, Yu C, Wu H, Shi Y, Kong X. An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. Front Oncol 2022;12:791867. [DOI: 10.3389/fonc.2022.791867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Davakis S, Vailas M, Kozadinos A, Sakarellos P, Karampa A, Korkolis D, Glantzounis G, Papalampros A, Felekouras E. Surgical Therapy of Hepatocellular Carcinoma: State of the Art Liver Resection. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach 2022. [DOI: 10.5772/intechopen.100231] [Reference Citation Analysis]
12 Zhou T, Zhang Y, Chen Y, Shan J, Wang J, Wang Y, Chang J, Jiang W, Chen R, Wang Z, Shi X, Yu Y, Li C, Li X. ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal. Front Oncol 2022;12:879963. [DOI: 10.3389/fonc.2022.879963] [Reference Citation Analysis]
13 Depciuch J, Parlinska-Wojtan M, Rahmi Serin K, Bulut H, Ulukaya E, Tarhan N, Guleken Z. Differential of cholangiocarcinoma disease using Raman spectroscopy combined with multivariate analysis. Spectrochim Acta A Mol Biomol Spectrosc 2022;272:121006. [PMID: 35151168 DOI: 10.1016/j.saa.2022.121006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ding GY, Ma JQ, Yun JP, Chen X, Ling Y, Zhang S, Shi JY, Chang YQ, Ji Y, Wang XY, Tan WM, Yuan KF, Yan B, Zhang XM, Liang F, Zhou J, Fan J, Zeng Y, Cai MY, Gao Q. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol 2022;76:608-18. [PMID: 34793865 DOI: 10.1016/j.jhep.2021.10.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
15 Servin F, Collins JA, Heiselman JS, Frederick-dyer KC, Planz VB, Geevarghese SK, Brown DB, Miga MI. Fat Quantification Imaging and Biophysical Modeling for Patient-Specific Forecasting of Microwave Ablation Therapy. Front Physiol 2022;12:820251. [DOI: 10.3389/fphys.2021.820251] [Reference Citation Analysis]
16 Gritskevich AA, Gurmikov BN, Baitman TP, Shipilova AN, Paichadze AA, Chzhao AV. Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-20-101-109] [Reference Citation Analysis]
17 Song J, Cui D, Wang J, Qin J, Wang S, Wang Z, Zhai X, Ma H, Ma D, Liu Y, Jin B, Liu Z. Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma. Cell Death Discov 2021;7:322. [PMID: 34716319 DOI: 10.1038/s41420-021-00721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology 2021;74:2021-31. [PMID: 34018229 DOI: 10.1002/hep.31914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
19 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 King G, Javle M. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Curr Oncol Rep 2021;23:108. [PMID: 34269915 DOI: 10.1007/s11912-021-01100-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Chang YC, Chen MH, Yeh CN, Hsiao M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 2020;10:E1377. [PMID: 32998289 DOI: 10.3390/biom10101377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, Gumus Y, Chebib A, Almohamad W, Innominato PF. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 2020;20:515. [PMID: 32493242 DOI: 10.1186/s12885-020-07004-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
23 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 622] [Cited by in F6Publishing: 599] [Article Influence: 207.3] [Reference Citation Analysis]